New pill aims to reverse liver scarring in fatty liver patients
NCT ID NCT07610837
First seen Jun 24, 2026 · Last updated Jul 30, 2026 · Updated 4 times
Summary
This study tests an experimental drug called AZD2389 in about 104 adults with fatty liver disease and advanced liver scarring (fibrosis). The drug is a pill that blocks a protein linked to scarring. Researchers will check if it safely lowers markers of liver damage over 24 weeks compared to a placebo. The goal is to see if the drug can improve liver health and potentially slow or reverse the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- AZD2389 (an oral drug that blocks a protein called FAP to reduce liver scarring)
- What this could lead to
- If successful, this could point toward a new treatment to slow or reverse liver scarring in people with fatty liver disease and advanced fibrosis.
- What could go wrong
- This is an early Phase 2 trial with only 104 participants, so results may not apply to everyone. The drug may not improve liver fibrosis or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATIC CIRRHOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research Site
RECRUITINGChandler, Arizona, 85224, United States
-
Research Site
RECRUITINGTucson, Arizona, 85712, United States
-
Research Site
RECRUITINGJupiter, Florida, 33458, United States
-
Research Site
RECRUITINGMiami, Florida, 33122, United States
-
Research Site
RECRUITINGPort Orange, Florida, 32127, United States
-
Research Site
RECRUITINGKansas City, Missouri, 64131, United States
-
Research Site
RECRUITINGSt Louis, Missouri, 63123, United States
-
Research Site
RECRUITINGLas Vegas, Nevada, 89106, United States
-
Research Site
RECRUITINGMorehead City, North Carolina, 28557, United States
-
Research Site
RECRUITINGRaleigh, North Carolina, 27607, United States
-
Research Site
RECRUITINGWestlake, Ohio, 44145, United States
-
Research Site
RECRUITINGYukon, Oklahoma, 73099, United States
-
Research Site
RECRUITINGClarksville, Tennessee, 37040, United States
-
Research Site
RECRUITINGAustin, Texas, 78757, United States
-
Research Site
RECRUITINGDenison, Texas, 75020, United States
-
Research Site
RECRUITINGGeorgetown, Texas, 78626, United States
-
Research Site
RECRUITINGHouston, Texas, 77004, United States
-
Research Site
RECRUITINGHouston, Texas, 77079, United States
-
Research Site
RECRUITINGSan Antonio, Texas, 78215, United States
-
Research Site
RECRUITINGSan Antonio, Texas, 78222, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can extra doses of an old drug reverse liver scarring?
- Can Weight-Loss surgery beat drugs for advanced liver damage?
- Navy beans take on fatty liver: a diet swap put to the test
- Could a cholesterol drug and a bile acid pill help reverse liver scarring?
- Stick-On ultrasound patch could spot liver damage without a specialist
- Food flavors on the breath may reveal hidden liver disease